Skip to content
MarketScale
‹ Back to IndustriesHealthcare

COVID-19 and the Concerns of the Healthcare Professional

On this episode of I Don’t Care with Kevin Stevenson, Stevenson goes big picture, sourcing insights from his vast network of healthcare professionals to determine the industry’s biggest concerns related to COVID-19 and the world’s slow move toward a new normal in the wake of the pandemic. Stevenson condensed those thoughts into five central concerns…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from I Don't Care on MarketScale.

Share

On this episode of I Don’t Care with Kevin Stevenson, Stevenson goes big picture, sourcing insights from his vast network of healthcare professionals to determine the industry’s biggest concerns related to COVID-19 and the world’s slow move toward a new normal in the wake of the pandemic.

Stevenson condensed those thoughts into five central concerns of healthcare workers:

Their Jobs

Many hospitals and other healthcare operations have furloughed or laid off staff, particularly due to lost revenue tied to elective procedures and more, and a continuation of the pandemic could lead to more cuts.

The Overall Economy

Healthcare and industry workers are by no means immune to the overall economic downturn caused by the pandemic, which has led to a decrease in insured patients, etc.

Safety in the Workplace

Like many, healthcare workers are generally concerned about contracting COVID-19 in the workplace, though hospitals and other facilities are perhaps the safest place to be due to precautions in place.

A Lack of Personal Protective Equipment

PPE, such as masks, gowns, gloves, face shields and more, are still hard to acquire for many healthcare operations, particularly smaller and more rural ones.

The Potential for a Vaccine Not Being Created

For many, a vaccine is the only true “end” in sight to the COVID-19 pandemic. While some are concerned that a vaccine may not be possible, Stevenson said he believes one will be created by the massive amount of effort being put forth to expedite one’s creation.

To hear all of Stevenson’s thoughts on these current concerns and the overall trends in healthcare at the moment, listen to the entire episode.

Catch up on previous episodes of I Don’t Care with Kevin Stevenson!

I Don't Care

Part of this channel

I Don't Care

Candid healthcare leadership conversations with Kevin Stevenson

Visit the channel →

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Recent advancements in healthcare, including gene therapies, early detection methods, and GLP-1 drugs, are influencing enterprise healthcare procurement strategies. These innovations are impacting benefit plan adjustments and procurement decision-making processes. The healthcare industry is experiencing a notable shift due to FDA-cleared treatments and predictive diagnostics.

  • 01Gene therapies and early detection methods are transforming healthcare procurement.
  • 02FDA-cleared treatments are prompting shifts in benefit plans.
  • 03Advancements are accelerating decision-making in healthcare procurement.

Jul 14, 2026

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512